MAPPER: Neoadjuvant Endocrine Treatment in HR+/HER2- Breast Cancer

Phase 2, open-label, single-arm trial of tamoxifen in breast cancer, sponsored by Medical College of Wisconsin. Primary endpoints: Change from baseline in the number of subjects with increased HER-1 receptor tyrosine kinases protein expression in tumors, Change from baseline in the number of subjects with increased HER-2 receptor tyrosine kinases protein expression in tumors and 2 more. Started Sep 2024; status: recruiting.